Although studies have assessed short-term mortality among patients with community-acquired pneumonia, there is limited data on prognosis and risk factors that affect long-term mortality. The mortality among patients enrolled at 4 sites of the Pneumonia Patient Outcome Research Team cohort study who survived at least 90 days after presentation to the hospital was compared with that among age-matched control subjects. Overall, 1419 of 1555 patients survived for 190 days, with a mean follow-up period of 5.9 years. There was significantly higher long-term mortality among patients with pneumonia than among age-matched controls. Factors significantly associated with long-term mortality were age (stratified by decade), do-not-resuscitate status, poor nutritional status, pleural effusion, glucocorticoid use, nursing home residence, high school graduation level or less, male sex, preexisting comorbid illnesses, and the lack of feverishness. This study demonstrates that there is significantly higher long-term mortality among patients with pneumonia than among age-matched controls and that long-term mortality largely is not affected by acute physiologic derangements.
hospitalizations annually due to pneumonia [2] . CAP alone accounts for 21 days of restricted activity per 100 persons each year, and, in 1994, the cost of treatment for CAP was $9.7 billion [3] .
Despite the substantially high morbidity and mortality associated with CAP, there have been a limited number of studies that examined the long-term prognosis of CAP or the risk factors for long-term mortality for patients with this illness. Two previous studies, which involved relatively small numbers of patients (i.e., !250), found that patients with CAP had a significantly higher long-term mortality than did agematched control subjects [4, 5] . In contrast to the present study, these studies did not distinguish patients who died within a time frame proximate to the acute illness (i.e., within 90 days after presentation to the hospital) from those who died during a longer followup period. Another recent study using Medicare administrative data found that patients hospitalized with CAP had significantly higher mortality than did ageand comorbidity-adjusted controls [6] . Several other previous studies examined the predictors of long-term mortality among patients with CAP; however, these studies were small in size and did not agree on the prognostic factors associated with long-term mortality [4, 5, [7] [8] [9] . Only one previous study of long-term mortality included low-risk patients treated in an outpatient setting [5] .
This work extends the follow-up of patients with CAP enrolled in the Pneumonia Patient Outcomes Research Team (PORT) cohort study to provide a better understanding of the long-term prognosis of this illness. The goals of this study were to (1) describe the mortality of CAP with long-term followup, (2) compare the long-term mortality among patients with CAP with that among age-matched control subjects, and (3) identify the factors associated with long-term mortality among patients with this illness.
PATIENTS AND METHODS
Study patients and sites. This study assessed the mortality after long-term follow-up of outpatients and inpatients with CAP who were enrolled in the Pneumonia PORT cohort study. The inclusion and exclusion criteria, methods of patient recruitment, and study sites are described elsewhere in detail [10] . In brief, patients who were у18 years of age, who had not been hospitalized within the last 10 days, and who were not HIV seropositive were enrolled. The Pneumonia PORT cohort study was conducted at 4 medical institutions in the United States and 1 in Canada from October 1991 through March 1994. This analysis was restricted to outpatients (4 sites) and inpatients (3 sites) with clinical and radiographic evidence of pneumonia enrolled at the 4 US sites; patients at the single Canadian site were excluded, because it was not possible to obtain accurate long-term follow-up data on mortality.
Baseline assessment. Baseline sociodemographic information and clinical data at presentation were assessed for all patients by study interviewers and during medical record review. If information from the patient was unobtainable because of mental status changes or language or communication barriers, a proxy respondent was used. Clinical data examined included medical history, findings of a physical examination, results of laboratory tests, and findings of chest radiography. Historical data included 19 common pneumonia-related symptoms [11] . Findings of physical examination included data on vital signs and an evaluation of mental status. Laboratory data, when requested by the managing physicians, included WBC count, hematocrit, blood urea nitrogen level, serum sodium level, liver enzyme levels, arterial blood gas levels, and results of pulse oximetry. Radiographic data included location of infiltrate, pattern of infiltrate (i.e., predominantly alveolar, predominantly interstitial, miliary, or mixed alveolar and interstitial), and presence of pleural effusion [12, 13] .
Severity of illness at presentation was assessed during the initial Pneumonia PORT cohort study with the pneumonia severity index (PSI) [14] . The PSI is a validated prediction rule for 30-day mortality in patients with CAP. This rule was based on 3 demographic characteristics, 5 comorbid illnesses, 5 physical examination findings, and 7 laboratory and radiographic findings recorded at the time of presentation. Patients are classified into 5 risk classes, with 30-day mortality ranging from 0.1% for class I (lowest risk) to 27% for class V (highest risk) among patients enrolled in the PORT cohort study. The Charlson comorbidity score was used to assign a comorbidity score for preexisting comorbid conditions [15, 16] . This score is based on 19 comorbid conditions, each of which has an associated prognostic weight that ranges from 1 to 6. The following comorbid conditions are included in the Charlson score: myocardial infarction, angina, cardiac arrhythmia, hypertension, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, diabetes, hemiplegia, moderate renal disease, any malignancy, moderate liver disease, metastatic solid tumor, and AIDS. The Charlson comorbidity score was used for risk adjustment in the model of long-term mortality because it has been previously validated for long-term (up to 1 year) mortality, whereas the PSI has only been validated for short-term (30-day) mortality. Moreover, use of the Charlson score, rather than a measure of risk derived from the PSI, in our models of long-term mortality allowed us to assess, in an unconstrained manner, the association between each of the individual 20 variables comprised by the PSI and long-term mortality.
Assessment of mortality. Short-term mortality was prospectively assessed 90 days after presentation for all patients enrolled in the Pneumonia PORT cohort study using methods described elsewhere [10] . The initial selection of a 90-day follow-up period was made to capture the vast majority of shortterm deaths attributable to the acute pneumonia. Our analyses demonstrate that, for patients with CAP, just over three-fourths of pneumonia-related deaths occurred within 30 days after presentation, and just under one-fourth of the deaths that occurred between days 30 and 90 were attributed to CAP [17] .
In the present study, long-term mortality was assessed using the National Death Index (NDI). The NDI is operated by the Centers for Disease Control and Prevention (Atlanta, GA) and includes all US death data since 1979 [18] . Previously validated methods were used to determine whether the NDI matches on deaths were true matches [19, 20] . Matches with probability scores of 110 were accepted as true matches, and scores of less than Ϫ10 were rejected as false matches. Matches with scores between 10 and Ϫ10 were further screened using secondary criteria described by Williams et al. [20] .
Patients were enrolled in the initial study and observed for assessment of short-term mortality from October 1991 through ). This plot demonstrates n p 1555 that, for all patients who presented with community-acquired pneumonia, increasing PSI risk class (i.e., from I to V) was significantly associated with decreased long-term survival (
, by the log-rank test).
June 1994, and mortality information was requested from the NDI for the period from January 1991 through December 1998. The validity of the data obtained from the NDI was assessed by comparing the prospectively determined patient mortality during the initial 90-day follow-up period with the corresponding mortality information obtained from the NDI. The NDI identified 163 (98.7%) of the 165 deaths identified during the prospective follow-up period and identified only 1 "false-positive" death among the 1419 short-term survivors identified prospectively.
Statistical analysis. Mortality from the time of presentation until the completion of long-term follow-up was described for the full study group ( ) using Kaplan-Meier n p 1555 plots. Data on all enrolled patients were included in this graph to illustrate the timing of death over a longer period of followup for each PSI risk class. Differences in long-term mortality were determined using the log-rank test, with consid-P ! .05 ered to be statistically significant. Long-term mortality was stratified by the 5 PSI risk classes.
Long-term mortality among patients in the Pneumonia PORT cohort was compared with the mortality in an agematched control cohort derived from US life table data [21, 22] . These comparisons were restricted to patients in the Pneumonia PORT cohort who survived 90 days after presentation with CAP. To assess the sensitivity of this comparison to the decision to restrict these analyses to patients with CAP who had survived 90 days, we repeated these analyses in patients who had survived 30 and 60 days after initial presentation, and the results did not change.
Our assessment of the factors associated with long-term mortality was also performed for patients who survived 90 days after presentation with CAP. Independent variables that were examined in this analysis included sociodemographic variables, medical history, physical examination findings, laboratory and radiographic findings, and comorbid conditions. To assess the factors that were univariately associated with long-term mortality following presentation with CAP, Kaplan-Meier productlimit methods with log-rank tests and univariable Cox proportional hazards models were used. Any variable that was significant ( ) in the univariable analysis was then entered P р .10 into a stepwise, multivariable Cox proportional hazard model. The method of Therneau et al. [23] was used to evaluate the proportional hazard assumption. A Cox-Snell residual plot was used to evaluate the goodness of fit of the final model [24] . Interactions between any 2 factors were assessed using crossproduct terms.
RESULTS
Of the 1555 patients enrolled in the Pneumonia PORT cohort study and eligible for this study, 136 patients (8.7%) died within 90 days of presentation, and an additional 472 (30.3%) died between day 91 and the end of the long-term follow-up period (mean follow-up duration, 5.9 years). Among all 608 patients who died, 8.7% died within 90 days after presentation to the hospital, 29.2% in year 1, 19.1% in year 2, 16.1% in year 3, 10.0% in year 4, and 25.4% in year 5 and beyond. Figure 1 shows the Kaplan-Meier plot of long-term survival by PSI class for all 1555 enrolled patients. Overall, long-term mortality was 39.1% and ranged from 6.2% for patients in PSI risk class I to 84.7% for those in PSI risk class V. Long-term mortality after CAP compared to average life expectancy. Figure 2 compares the long-term mortality among patients who survived beyond day 90 ( ) with n p 1419 that of an age-matched cohort for whom data were derived from US life tables [21] . There was a statistically significant higher mortality rate among patients with CAP across all age groups in these 2 populations.
Predictors of long-term mortality for pneumonia. The sociodemographic characteristics, medical history, and physical examination findings, comorbid illnesses, and laboratory and radiographic findings with a univariable association with longterm mortality ( ) are shown in table 1. Long-term mor-P ! .05 tality was lower among outpatients than among inpatients (11% vs. 48%;
). P ! .001 Table 2 shows the variables that were independently associated with long-term mortality in a multivariable Cox survival model. Sociodemographic factors associated with mortality were age (stratified by decade), high school graduation level or less, male sex, and nursing home residence. In addition, comorbid conditions represented by the Charlson comorbidity score, pleural effusion, and steroid use were independently associated with long-term mortality. The only "acute" pneumonia-related factors identified in the multivariable model were feverishness at presentation (associated with reduced mortality) and the presence of a pleural effusion on the chest radiograph obtained at baseline. In the multivariable survival model, there were no significant interactions between the Charlson comorbidity score and the presence of pleural effusion or fever.
DISCUSSION
This study demonstrates that mortality during long-term follow-up of patients with CAP is higher than that among agematched controls; approximately one-third of patients with CAP who survived 90 days after presentation to the hospital died during the 6 years after presentation. Our results support the observations of previous work on the long-term mortality of CAP that demonstrated that the prognostic implications of an episode of CAP continue far past the initial illness [4] [5] [6] . A previous study of sepsis, which is frequently secondary to CAP, also demonstrated that acute sepsis was associated with decreased long-term survival among patients, compared with survival in an age-and comorbidity-adjusted control population [25] . In addition, these results demonstrate that age and comorbid conditions, rather than abnormal acute physiologic or laboratory findings, become the factors most strongly associated with death for those who die 190 days after presentation [17] . Sir William Osler stated that "[p]neumonia may well be called the friend of the aged. Taken off by it in an acute, short, not often painful illness, the old man escapes those 'cold gradations of decay' so distressing to himself and to his friends" [26, pp. 109-12] . Our current work extends Osler's observation that older patients with pneumonia often die during the acute phase of the illness by demonstrating that mortality among these patients remains significantly higher than estimated on the basis of their age alone [17] . The most likely explanation for this finding is that many of the chronic illnesses that predispose patients to development of CAP-including chronic cardiopulmonary disease, cancer, and neurologic disease-also contribute to its long-term mortality [9, 27, 28] . In our study, comorbid conditions (reflected by the Charlson comorbidity score), age, and nursing home residence were the strongest predictors of long-term mortality, whereas the only "acute" pneumonia-related factors that were significantly associated with long-term mortality in the multivariable model were fever and the presence of a pleural effusion. It is possible that the associations of both of these pneumonia-related factors with long-term mortality can be explained by their relationship with comorbid conditions and age, which may not have been completely adjusted for in the multivariable models. For example, pleural effusions may be caused by acute pneumonic illness but may also be attributed to congestive heart failure, chronic renal disease, or malignancy. Although previous studies of short-term mortality after CAP in older persons have shown that patients who report symptoms such as fever or chills have lower mortality than those who do not report these symptoms, both of these factors are inversely correlated with age, which could explain the protective nature of fever in this study [29, 30] . In addition, factors that have been associated with shortterm mortality, including educational status and male sex, were independently associated with long-term mortality among patients with CAP [31, 32] . Steroid use was also associated with long-term mortality and is probably a marker of severe underlying pulmonary disease, of other serious coexisting illness, or of underlying immunosuppression.
These findings suggest that, in contrast to short-term mortality, the severity of the physiologic derangements at initial presentation (e.g., abnormal vital signs and laboratory findings) are not significantly associated with an increased long-term mortality, after adjustment for age, comorbid illness, and nursing home residence. Our results do not concur with previous smaller studies that demonstrated that acute physiologic derangements were associated with long-term mortality [4, 5, 7] . These differences are probably due to the inclusion of patients who died within 90 days after presentation in the former mortality analyses, which would increase the magnitude of the effect of such abnormal acute physiologic findings on long-term mortality.
This study has several limitations that should be acknowledged. First, we did not prospectively obtain follow-up clinical information after 90 days and, therefore, were not able to assess the effect of additional comorbid conditions or other intermediate outcome events on long-term mortality. Second, it was necessary to exclude a sizeable proportion of patients enrolled in the initial pneumonia PORT cohort study because of our inability to obtain accurate mortality data for the patients enrolled at the site in Canada. Moreover, not all patients who were eligible for the study were enrolled, which may limit the generalizability of our findings [10] . Although the diminished size of the study population is a limitation, the baseline sociodemographic and clinical characteristics of the patients at the Canadian study site were not significantly different from those of the patients at the 4 sites in the United States. In addition, we were not able to identify an optimal control group that was similar to the patients with CAP with respect to the type and severity of comorbid conditions. As a result, we were unable to quantify the association of the acute episode of CAP with long-term mortality independent of coexisting comorbid conditions.
In conclusion, this study demonstrates that there is substantial mortality after a long-term follow-up period among patients with CAP and that sociodemographic factors, comorbid conditions, and age are the strongest independent predictors of long-term mortality. These results suggest that, although the impact of pneumonia on mortality predominantly occurs in the first year after the acute illness, this association with mortality continues for at least 5 years after the initial episode. Long-term mortality appears to be associated with intrinsic characteristics of the patient, which are largely not modifiable by medical care. Clinicians who treat patients with CAP should keep these results in mind when discussing longterm prognosis with patients and their families.
